Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Ranking of 20 Drug Companies' Sales Forces Shows Productivity Flat or Declining
- A ranking of drug company sales productivity shows Gilead gets the most revenues in return for every dollar invested in reps and marketing. At the other end of the table, Sepracor gets the least bang for its sales, general and administrative buck see table below. ...
- Blog posts 2009-02-24
- Ranking of 20 Drug Companies Shows Sales Force Effectiveness Reaching Plateau
- A ranking of 20 drug companies by sales and marketing productivity shows that 10 companies saw upward trends in effectiveness in Q2 2009. Last quarter, 13 companies had upward trends. The numbers indicate that companies have started to reach a plateau in their efforts to wring more revenues out of...
- Blog posts 2009-08-07
- Pfizer Leads in Layoffs While Drug Prices Soar
- Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...
- Blog posts 2008-04-10
- Ranking of 20 Drug Companies by Sales Force Effectiveness Shows Improvement in Q1
- A ranking of 20 drug companies on sales and marketing productivity shows upward trends in effectiveness in Q1 2009. At the top of the table is AIDS drug specialist Gilead. At the bottom of the table is vanity pharma play Medicis. by Jim Edwards
- Blog posts 2009-05-14
- Pharma Roundup: Schering-Plough Surveys Investors, Wyeth Defended, and More
- Schering-Plough shareholders to have say on executive compensation, U.S. drug sales predictions lowered, McCain and Obama both promise hard line on Big Pharma. Also: two lawyers condemn unfounded anti-Wyeth opinions. by John Maas
- Blog posts 2008-10-29
Additional Resources
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- BMS Sales Increase Masks Looming Patent Cliff Disaster
- Bristol-Myers Squibb is dependent for half its revenues on just three drugs, and those brands will all be generic by 2012, the NYT reports. The article asks whether BMS can survive on its own or be acquired, possibly by Sanofi Aventis: Of Bristol-Myers’s $4.5 billion in drug...
- Blog posts 2009-01-28
- Walgreens Raises Dividend: 34 Years Straight and Counting
- Ockham Research submits: Walgreen Company WAG has raised their dividend for the 34th year in a row, and this hike is more substantial than most at 22%. The anticipated yearly dividend will be 55 cents, raised from 45 cents over the previous four quarters. As the company’s...
- External links 2009-07-09
- International Drug & Explosives Detection Company IDenta Releases Progress Report for U.S. Operations -- Accutest(R)-IDenta Partnership on Track for Market Leadership in 2008
- IDenta Corp. (PINKSHEETS: IDTA) today released a summary detailing the progress that has been made between the company and its U.S. partnership with Jant Pharmacal - Accutest®. The partnership has been in full effect for approximately six months during which time the two companies have engaged in an almost total...
- Research articles 2007-10-29
- Oberto Sausage Company Announces New Sales Agency Partnerships
- SEATTLE -- The Oberto Sausage Company today announced new partnerships with several industry leading sales agencies to represent Obertoâ??s full line of meat snack products. As part of its...
- Research articles 2009-05-28
- Auriga to Host Investor Conference Call to Discuss Strategic Goals and Progress in Pharmaceutical Marketplace; Company CEO to Detail High-Growth Strategy Through Brand Acquisitions, New Drug Development and National Sales Operations
- NORCROSS, Ga. -- Auriga LaboratoriesTM, Inc. (OTCBB:ARGA), a specialty pharmaceutical company committed to high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, will host an investor conference call, with a simultaneous webcast, today, Wednesday, August 2, 2006, at 4:01 pm Eastern, to discuss recent Company events,...
- Research articles 2006-08-02
- Make good deeds part of business strategy. (Executive Word).(Interview)
- This year marks the 20th anniversary of The Orphan Drug Act ODA, which provides incentives to companies that develop drugs for disorders that affect 200,000 or fewer people. Such groups usually are too small to be considered profitable markets for large pharmaceutical companies. Sigma-Tau Pharmaceuticals Inc.,...
- Research articles 2003-02-01
- Microgenics Announces Management Buyout From Hoffman La-Roche; Leading Diagnostics Manufacturer Re-Emerges as Independent Company
- PLEASANTON, Calif.--BW HealthWire--Oct. 28, 1998--Microgenics Corporation, a leading supplier of diagnostic reagents, announced today the acquisition of the CEDIAR immunoassay technology and product line from Hoffman La-Roche in a management-led buyout, with the financial support of Morgan Stanley Ventures. Microgenics' strategy will be to make its drugs of abuse,...
- Research articles 1998-10-28
- Applera Corporation F1Q08 (Qtr End 9/30/07) Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you sir. [Operator’s instructions.] One moment while we compile a list of questions. Our first question will come from the line of Ross Muken of Deutsche Bank, please proceed. Ross Muken – Deutsche Bank Good morning everyone. Mark P. Stevenson –...
- Earnings calls 2007-10-25
- GlaxoSmithKline Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionKevin Wilson - Citigroup Yeah, thank you this Kevin Wilson from Citigroup in London. Three questions, if I may, JP. Firstly, in the U.S., the 2% decline in sales in the quarter. Could you break out the volume and any price element you saw, and perhaps also comment...
- Earnings calls 2007-07-25
- Emerging market for medicines
- When Haruo Naito, chief executive of Eisai, the Japanese pharmaceutical company, signalled his continued interest in western markets by inaugurating his company's European headquarters in the UK last month, his mind was already elsewhere."We have already finished our investments in all major areas in the US and Europe," he...
- External links 2009-08-03
- Forest Laboratories: Finding Ways to Bring Drugs to Market — Fast
- Pfizer may be big, but Forest Laboratories is nimble. The smaller company competes by ushering drugs through FDA red tape in record time. Giant: Pfizer Shadow Success: Forest Laboratories, Inc. Pfizer market cap: $96.56 billion;...
- Articles 2009-06-10
- AZ outlined 'weight-neutral' Seroquel pitch
- More internal documents have surfaced in AstraZeneca's Seroquel fight, Bloomberg reports. The latest: A "dear colleague" letter from marketing official Debbie Holdsworth, stating that AstraZeneca's "global strategy is to demonstrate to consumers that Seroquel has a weight-neutral profile." That letter was dated 2001, plaintiff's attorney Ed Blizzard pointed out, four...
- News items 2009-10-08
- ImClone Systems Inc. Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator [Operator Instructions]. Your first question comes from May-Kin Ho of Goldman Sachs. May-Kin Ho - Goldman Sachs Hi. I guess, I wanted to ask question about really how your payment from Bristol would be recognized and how we should going forward project out...
- Earnings calls 2007-10-25
- CVS gains in general merchandise, as drug chains advance in recession
- As drug chains reposition and promote to win market share in the recession, Easter put a hop into retail at CVS during the second quarter, with comparable store sales for general merchandise up three percent. Even taking out extraordinary factors, including the holiday and a raise in...
- Blog posts 2009-08-11
- << Previous
- page 1 of 1
- Next >>
